insights_auto
Why is LYEL down 9,19%?
Dive Deeperchevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
USD 7,51
arrow_downward
-9,19%(-0,76) 1D
13 Okt., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
USD 8,27
High
USD 8,27
Low
USD 7,39
Mkt. cap
184,03 m
Avg. vol.
134,19 k
Volume
0,00
52-wk high
USD 45,00
52-wk low
USD 7,39
EPS
-USD 12,01
Beta
-0,03
Shares outstanding
24,50 m
No. of employees
161
Open
USD 8,27
High
USD 8,27
Low
USD 7,39
Mkt. cap
184,03 m
Avg. vol.
134,19 k
Volume
0,00
52-wk high
USD 45,00
52-wk low
USD 7,39
EPS
-USD 12,01
Beta
-0,03
Shares outstanding
24,50 m
No. of employees
161
News stories
From web sources and news partners
Investing.com Nigeria
·
8 uur gelede
Lyell Immunopharma CMO sells $3,641 in shares for tax withholding By Investing.com
ad-hoc-news.de
·
10 uur gelede
Lyell advances LYL273: what it means for Lyell Immunopharma stock
Stock Titan
·
14 uur gelede
An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares.
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, Kalifornië, Verenigde State van Amerika
Sector-
Websitelyell.com